Listed

Pelthos Therapeutics Inc.

PTHSNYSECIK 1919246HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$15.6mRevenue, Q2 FY2026, three months to 2026-06-30$15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 13, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$15.6mRevenue, Q2 FY2026, three months to 2026-06-30$15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figureSign changed from a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−111.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Revenue: $15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figureNo year-earlier figure to compare
  • Net margin−150.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Revenue: $15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figureNo year-earlier figure to compare
  • Diluted EPS−$6.62Diluted EPS, Q2 FY2026, three months to 2026-06-30−$6.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure−25.1% on a year earlier
  • Free cash flow−$7.7mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$7.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Report this figure−1615.0% on a year earlier

Last eight quarters

Full statements
Revenue$15.6mOperating margin −111.0%
Diluted EPS−$6.62, Q2 FY2026
Free cash flow−$7.7m, Q2 FY2026
Pelthos Therapeutics Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure0.3Revenue, Q3 FY2025, three months to 2025-09-30$294.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure16.5Revenue, Q4 FY2025, three months to 2025-12-31$16.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure10.9Revenue, Q1 FY2026, three months to 2026-03-31$10.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure15.6Revenue, Q2 FY2026, three months to 2026-06-30$15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(5225.2%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$15.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Revenue: $294.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(72.7%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$12.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $16.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(120.0%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$13.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Revenue: $10.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(111.0%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$17.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Revenue: $15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(5523.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Revenue: $294.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figure(131.3%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$21.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Revenue: $16.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013. Derived: 12-month figure less the 9-month figure.Report this figure(229.9%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$25.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Revenue: $10.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(150.1%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Revenue: $15.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Diluted EPS$ per share(2.93)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figurenot reported (Diluted EPS not reported)(3.21)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$3.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(5.29)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$5.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure(5.30)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$5.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001753926-25-001764.Report this figurenot reported (Diluted EPS not reported)(7.57)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$7.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(6.62)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$6.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001919246-26-000113.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(0.6)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$632.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(0.4)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$447.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(13.3)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Capital expenditure: $194.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q/A filed 2026-08-13, accession 0001919246-26-000111.Report this figure(7.7)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$7.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001919246-26-000113. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$16.8mOperating margin −193.1%
Diluted EPS−$23.04, FY2025
Free cash flow−$22.7m, FY2025
Pelthos Therapeutics Inc., key figures for the last five fiscal years
Line itemUnitFY2022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)not reported (Revenue not reported)0.0Revenue, FY2024, twelve months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure16.8Revenue, FY2025, twelve months to 2025-12-31$16.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)(193.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$32.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013.Revenue: $16.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue of zero not reported)(257.9%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$43.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-19, accession 0001919246-26-000013.Revenue: $16.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(5.78)Diluted EPS, FY2023, twelve months to 2023-12-31−$5.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-27, accession 0001753926-25-000503.Report this figure(14.27)Diluted EPS, FY2024, twelve months to 2024-12-31−$14.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure(23.04)Diluted EPS, FY2025, twelve months to 2025-12-31−$23.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)(5.8)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-19, accession 0001919246-26-000013.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure(22.7)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$22.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-19, accession 0001919246-26-000013.Capital expenditure: $99.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-19, accession 0001919246-26-000013.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Pelthos Therapeutics Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
AIGH Capital Management LLC2026-06-30$9.3m329,098New+329,098
Murchinson Ltd.2026-06-30$8.6m304,302Added+7,988
Ikarian Capital, LLC2026-06-30$7.3m256,598Unchanged
BOOTHBAY FUND MANAGEMENT, LLC2026-06-30$2.9m101,976Added+20,118
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$2.7m97,134Added+4,041
CANTOR FITZGERALD, L. P.2026-06-30$1.1m38,123Reduced−3,300
CANTOR FITZGERALD, L. P.2026-06-30$1.1m38,123Reduced−3,300
J. Goldman & Co LP2026-06-30$1.1m38,075Reduced−12,340
DIADEMA PARTNERS LP2026-06-30$700.1k24,773Unchanged
WEXFORD CAPITAL LP2026-06-30$632.0k22,364New+22,364

Recent filings

All 243 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Pelthos Therapeutics Inc., recent filings
FiledFormWhat it isAccession number
2026-10-0121:15 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001919246-26-000125
2026-08-1821:00 ETDEF 14AProxy statementPeriod 2026-09-290001919246-26-000120
2026-08-1311:20 ET10-QQuarterly reportPeriod 2026-06-300001919246-26-000113
2026-08-1311:15 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001919246-26-000112
2026-08-1311:06 ET10-Q/AQuarterly report, amendedPeriod 2026-03-310001919246-26-000111
2026-08-1311:00 ET8-K4.02 Non-reliance on financial statements0001919246-26-000110
2026-05-2821:01 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001919246-26-000085
2026-05-2121:00 ET8-K4.01 Change of auditor; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001919246-26-000078
2026-05-1411:08 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001919246-26-000071
2026-05-1411:06 ET10-QQuarterly reportPeriod 2026-03-310001919246-26-000070

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 19, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1919246
Tickers
PTHS
Exchange
NYSE
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
NV
Filer category
<br>Emerging growth company
Former names
Channel Therapeutics Corp (to 2025-05-27); Chromocell Therapeutics Corp (to 2024-11-15)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.